We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
News

BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
News

BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioRelix and Dalton Medicinal Chemistry have jointly announced a research collaboration to discover new therapeutics.

Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.

Brian Dixon, BioRelix CEO commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery of new entities for treating infectious diseases. Their expertise, coupled with our proprietary and leading position in RiboSwitch technology will lead to important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with BioRelix in the discovery of much needed new anti-infective agents. The team at BioRelix has clearly established an exceptionally innovative approach to anti-infectives."

Advertisement